{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Recurrent+Cancer&page=5", "query": { "condition": "Recurrent Cancer", "page": 5 }, "page_size": 10 }, "pagination": { "page": 5, "page_size": 10, "total_count": 8498, "total_pages": 850, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Recurrent+Cancer&page=6&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Recurrent+Cancer&page=4&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-23T18:07:57.252Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04729959", "title": "Testing the Addition of the Immune Therapy Drugs, Tocilizumab and Atezolizumab, to Radiation Therapy for Recurrent Glioblastoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diffuse Astrocytoma, IDH-Wildtype", "Recurrent Glioblastoma" ], "interventions": [ { "name": "Atezolizumab", "type": "BIOLOGICAL" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Conventional Surgery", "type": "PROCEDURE" }, { "name": "Fractionated Stereotactic Radiation Therapy", "type": "RADIATION" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Tocilizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE", "RADIATION" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 61, "start_date": "2022-03-11", "completion_date": "2027-08-20", "has_results": true, "last_update_posted_date": "2026-09-23", "last_synced_at": "2026-10-23T18:07:57.252Z", "location_count": 110, "location_summary": "Anaheim, California • Bellflower, California • Los Angeles, California + 89 more", "locations": [ { "city": "Anaheim", "state": "California" }, { "city": "Bellflower", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04729959" }, { "nct_id": "NCT00005859", "title": "Tipifarnib in Treating Patients With Recurrent or Progressive Malignant Glioma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Brain and Central Nervous System Tumors" ], "interventions": [ { "name": "tipifarnib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 136, "start_date": "2000-05-16", "completion_date": "2006-08-01", "has_results": false, "last_update_posted_date": "2018-06-26", "last_synced_at": "2026-10-23T18:07:57.252Z", "location_count": 11, "location_summary": "Los Angeles, California • San Francisco, California • Bethesda, Maryland + 8 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT00005859" }, { "nct_id": "NCT03624036", "title": "Study to Evaluate the Safety and Tolerability of Brexucabtagene Autoleucel (KTE-X19) in People With Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Relapsed/Refractory Chronic Lymphocytic Leukemia and Relapsed/Refractory Small Lymphocytic Lymphoma" ], "interventions": [ { "name": "brexucabtagene autoleucel", "type": "BIOLOGICAL" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Kite, A Gilead Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2018-11-15", "completion_date": "2022-11-18", "has_results": true, "last_update_posted_date": "2023-11-18", "last_synced_at": "2026-10-23T18:07:57.252Z", "location_count": 21, "location_summary": "Phoenix, Arizona • Los Angeles, California • Stanford, California + 17 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03624036" }, { "nct_id": "NCT06414434", "title": "BTX-A51 in Patients With Liposarcoma or CIC-rearranged Sarcoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Liposarcoma", "Recurrent Liposarcoma", "Metastatic Liposarcoma", "Unresectable Liposarcoma", "MDM2 Gene Amplification", "Myxoid Liposarcoma", "CIC-Rearranged Sarcoma" ], "interventions": [ { "name": "BTX-A51", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Michael Wagner, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2024-09-30", "completion_date": "2027-06-01", "has_results": false, "last_update_posted_date": "2026-07-01", "last_synced_at": "2026-10-23T18:07:57.252Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT06414434" }, { "nct_id": "NCT03075072", "title": "Hippocampal Sparing Whole Brain Radiation Versus Stereotactic Radiation in Patients With 5-20 Brain Metastases: A Phase III, Randomized Trial", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Brain Metastases" ], "interventions": [ { "name": "Whole brain radiation", "type": "RADIATION" }, { "name": "Stereotactic radiation (SRS)", "type": "RADIATION" } ], "intervention_types": [ "RADIATION" ], "sponsor": "Brigham and Women's Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 196, "start_date": "2017-04-10", "completion_date": "2027-09-30", "has_results": true, "last_update_posted_date": "2026-09-29", "last_synced_at": "2026-10-23T18:07:57.252Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03075072" }, { "nct_id": "NCT03279692", "title": "Phase II Trial of Pembrolizumab in Recurrent or Residual High Grade Meningioma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "High Grade Meningioma" ], "interventions": [ { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 26, "start_date": "2017-11-07", "completion_date": "2026-12-31", "has_results": true, "last_update_posted_date": "2026-10-21", "last_synced_at": "2026-10-23T18:07:57.252Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03279692" }, { "nct_id": "NCT07227571", "title": "Genetically Engineered Cells (FH-FOLR1 ST CAR T Cells) for the Treatment of Advanced Refractory or Recurrent/Progressive Osteosarcoma, FIERCe Trial", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Osteosarcoma", "Recurrent Osteosarcoma", "Refractory Osteosarcoma" ], "interventions": [ { "name": "FH FOLR1 ST CAR T-cells", "type": "BIOLOGICAL" }, { "name": "Leukapheresis", "type": "PROCEDURE" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Biopsy Procedure", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE", "DRUG" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "75 Years", "sex": "ALL", "summary": "1 Year to 75 Years" }, "enrollment_count": 30, "start_date": "2026-01-16", "completion_date": "2044-01-31", "has_results": false, "last_update_posted_date": "2026-09-01", "last_synced_at": "2026-10-23T18:07:57.252Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT07227571" }, { "nct_id": "NCT05673967", "title": "Real-World Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Relapsed and Refractory Multiple Myeloma (RRMM)" ], "interventions": [ { "name": "Non-Interventional", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 62, "start_date": "2023-01-09", "completion_date": "2025-03-28", "has_results": false, "last_update_posted_date": "2025-04-25", "last_synced_at": "2026-10-23T18:07:57.252Z", "location_count": 1, "location_summary": "Tarrytown, New York", "locations": [ { "city": "Tarrytown", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05673967" }, { "nct_id": "NCT04423211", "title": "Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Biochemically Recurrent Prostate Carcinoma", "Metastatic Prostate Carcinoma", "Prostate Adenocarcinoma", "Stage IVB Prostate Cancer AJCC v8" ], "interventions": [ { "name": "3-Dimensional Conformal Radiation Therapy", "type": "RADIATION" }, { "name": "Apalutamide", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Degarelix", "type": "DRUG" }, { "name": "External Beam Radiation Therapy", "type": "RADIATION" }, { "name": "Fluciclovine F18", "type": "OTHER" }, { "name": "Goserelin Acetate", "type": "DRUG" }, { "name": "Intensity-Modulated Proton Therapy", "type": "PROCEDURE" }, { "name": "Intensity-Modulated Radiation Therapy", "type": "RADIATION" }, { "name": "Leuprolide Acetate", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Relugolix", "type": "DRUG" }, { "name": "Stereotactic Body Radiation Therapy", "type": "RADIATION" }, { "name": "Triptorelin", "type": "DRUG" }, { "name": "Volume Modulated Arc Therapy", "type": "RADIATION" } ], "intervention_types": [ "RADIATION", "DRUG", "PROCEDURE", "OTHER" ], "sponsor": "ECOG-ACRIN Cancer Research Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 804, "start_date": "2020-10-08", "completion_date": "2032-12-31", "has_results": false, "last_update_posted_date": "2026-08-19", "last_synced_at": "2026-10-23T18:07:57.252Z", "location_count": 341, "location_summary": "Anchorage, Alaska • Fairbanks, Alaska • Phoenix, Arizona + 240 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT04423211" }, { "nct_id": "NCT01056614", "title": "Fludarabine Phosphate, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Peripheral Blood Stem Cell Transplant, Tacrolimus, and Methotrexate in Treating Patients With Myeloid Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Accelerated Phase Chronic Myelogenous Leukemia", "Adult Acute Myeloid Leukemia in Remission", "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities", "Adult Acute Myeloid Leukemia With Del(5q)", "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)", "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)", "Blastic Phase Chronic Myelogenous Leukemia", "Childhood Acute Myeloid Leukemia in Remission", "Childhood Chronic Myelogenous Leukemia", "Childhood Myelodysplastic Syndromes", "Chronic Phase Chronic Myelogenous Leukemia", "de Novo Myelodysplastic Syndromes", "Hematopoietic/Lymphoid Cancer", "Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable", "Previously Treated Myelodysplastic Syndromes", "Recurrent Adult Acute Myeloid Leukemia", "Recurrent Childhood Acute Myeloid Leukemia", "Relapsing Chronic Myelogenous Leukemia" ], "interventions": [ { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "busulfan", "type": "DRUG" }, { "name": "anti-thymocyte globulin", "type": "BIOLOGICAL" }, { "name": "tacrolimus", "type": "DRUG" }, { "name": "methotrexate", "type": "DRUG" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" }, { "name": "allogeneic hematopoietic stem cell transplantation", "type": "PROCEDURE" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "PROCEDURE", "OTHER" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "60 Years", "sex": "ALL", "summary": "Up to 60 Years" }, "enrollment_count": 23, "start_date": "2004-09", "completion_date": "2016-04", "has_results": false, "last_update_posted_date": "2016-05-06", "last_synced_at": "2026-10-23T18:07:57.252Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT01056614" } ] }